Clinical trial
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00293345 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00293345 |
|---|---|
| Title | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
| Official title | A Phase I Study of a Prolonged Infusion of Triapine in Combination With a Fixed Dose Rate of Gemcitabine in Patients With Advanced Solid Tumors and Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma and 50 more |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, triapine |
| Enrollment | 30 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2012 |
| First posted | Feb 17, 2006 |
| Last update posted | Sep 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: